TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: Acute Respiratory Failure After Cardio Thoracic Surgery: Non Invasive Ventilation (VNI) by BIPAP Vision Versus OPTIFLOW System, Comparison.
Brief Summary: The OPTIFLOW ™ use is becoming more common in acute respiratory failure cases, but its place in relation to VNI (Bi-PAP mode) is not yet defined. OPTIFLOW ™ vs the VNI comparison of the use, in the immediate postoperative period, should lead to define the role of each technique and lead to a optimal rationalization of patients management with acute respiratory failure after surgery.


Options:
A: All-cause day-28 mortality (28 days)
B: Failure of the ventilation system (One week)
C: Tidal variation (Twenty minutes after each oxygen therapy. (At the end of each oxygen therapy))
D: Post-extubation respiratory failure and Reintubation rate (3 months)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Acute Respiratory Failure After Cardio Thoracic Surgery: Non Invasive Ventilation (VNI) by BIPAP Vision Versus OPTIFLOW System, Comparison.
Brief Summary: The OPTIFLOW ™ use is becoming more common in acute respiratory failure cases, but its place in relation to VNI (Bi-PAP mode) is not yet defined. OPTIFLOW ™ vs the VNI comparison of the use, in the immediate postoperative period, should lead to define the role of each technique and lead to a optimal rationalization of patients management with acute respiratory failure after surgery.


Options:
A: Number of patients with hypoxemia (defined as a PaO2/FiO2 ratio <300) after pulmonary lobectomy in patients with lung cancer (during the first 96 hours after surgery)
B: Oxygenation (PaO2/FiO2 ratio) (Up to 48 hours after extubation)
C: Respiratory failure after extubation (72 hours)
D: Failure of the ventilation system (One week)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As A Maintenance Therapy In Subjects With Ulcerative Colitis
Brief Summary: The study proposes to assess whether compared to placebo, CP-690,550 is effective, safe, and tolerable maintenance therapy in subjects with Ulcerative Colitis (UC). The study proposes to assess whether compared to placebo, CP-690,550 maintenance therapy more effectively achieves mucosal healing and improves quality of life in subjects with UC.The study proposes to assess CP-690,550 pharmacokinetic exposure during maintenance therapy in subjects over the age of 18 years with UC.


Options:
A: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 3 (Month 3); Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Month 3 (Baseline, Month 3); Percentage of Participant With Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) Less Than 2.6 at Month 3 (Month 3)
B: Number of Participants With Remission Based on Modified Mayo Score at Month 6 (Month 6)
C: Percentage of Participants In Remission at Week 52 (Week 52)
D: Percentage of Participants With Clinical Response (Week 8)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As A Maintenance Therapy In Subjects With Ulcerative Colitis
Brief Summary: The study proposes to assess whether compared to placebo, CP-690,550 is effective, safe, and tolerable maintenance therapy in subjects with Ulcerative Colitis (UC). The study proposes to assess whether compared to placebo, CP-690,550 maintenance therapy more effectively achieves mucosal healing and improves quality of life in subjects with UC.The study proposes to assess CP-690,550 pharmacokinetic exposure during maintenance therapy in subjects over the age of 18 years with UC.


Options:
A: Clinical response (8 weeks)
B: Percentage of Participants In Remission at Week 52 (Week 52)
C: Percentage of Participants With Remission at Week 8 (Week 8)
D: Induction Study - Number of Participants With Clinical Remission at Week 8 (As Per Global Definition) (Week 8); Induction Study - Number of Participants With Clinical Remission at Week 8 (As Per US Definition) (Week 8); Maintenance Study: Number of Participants With Clinical Remission at Week 44 (As Per Global Definition) (Week 44); Maintenance Study: Number of Participants With Clinical Remission at Week 44 (as Per US Definition) (Week 44)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Effects of Dietary and Dialysate Sodium Reduction on Body Fluid Volume and Inflammatory State in Hemodialysis Patients. A Prospective Randomized Controlled Study
Brief Summary: Objective: To evaluate the influence of dietary sodium reduction on body fluid volume and inflammatory state in hemodialysis (HD) patients.

Design: Prospective controlled randomized study. Setting: Dialysis Unit of Botucatu Medical School Hospital, Sao Paulo State University, Brazil.

Patients: Adult patients on HD for at least 30 days and C-reactive protein (CRP) ≥ 0.7 mg/dl were randomly allocated into two groups: Group A: 21 patients treated with a 2g sodium restriction in their habitual diet, and Group B: 18 controls. Inflammatory, biochemical, hematological and nutritional markers, as well as dialysis dosage were assessed at baseline and after 8 and 16 weeks.


Options:
A: Office systolic and diastolic BP readings (9 months)
B: Reduction in blood pressure (Six months)
C: Time Specific Interdialytic Weight Gain (Baseline) (Baseline); Time Specific Interdialytic Weight Gain (8 Weeks) (8 weeks); Time Specific Interdialytic Weight Gain (12 Weeks) (12 weeks); Time Specific Interdialytic Weight Gain (16 Weeks) (16 weeks); Time Specific Dietary Sodium Intake (Baseline) (Baseline); Time Specific Dietary Sodium Intake (8 Weeks) (8 weeks); Time Specific Dietary Sodium Intake (16 Weeks) (16 weeks); Time Specific Change From Baseline in Dietary Sodium Intake (Baseline to 8 Weeks) (Baseline to 8 weeks); Time Specific Change From Baseline in Dietary Sodium Intake (Baseline to 16 Weeks) (Baseline to 16 weeks)
D: C-reactive protein (up to 16 weeks); interleukin-6 (up to 16 weeks); alpha tumor necrosis serum concetrations (up to 16 weeks)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis.
Brief Summary: This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis: oral steroids, azathiopurine/6-mercaptopurine, or anti-TNF-alpha therapy.


Options:
A: Percentage of Participants With Remission at Week 8 (Week 8)
B: Percentage of Participants With Remission at Week 8 (Week 8)
C: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)); Number of Participants With Serious Infections as Treatment Emergent Adverse Events (TEAEs) (Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)); Number of Participants With Laboratory Test Abnormalities (Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)); Number of Participants With Vital Sign Abnormalities (Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)); Number of Participants With Clinically Significant Changes in Physical Examinations From Baseline (Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)); Number of Participants With Electrocardiogram (ECG) Abnormalities (Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)); Incidence Rates for Adjudicated Cardiovascular, Malignancy, Opportunistic Infections and Thromboembolic Safety Events (Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group))
D: Percentage of Participants With Clinical Response (Week 8)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis.
Brief Summary: This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis: oral steroids, azathiopurine/6-mercaptopurine, or anti-TNF-alpha therapy.


Options:
A: Number of Participants in Clinical Response Through Week 54 (Induction Baseline, Week 0 through Week 54)
B: Percentage of Participants With Remission at Week 8 (Week 8)
C: Induction Study - Number of Participants With Clinical Remission at Week 8 (As Per Global Definition) (Week 8); Induction Study - Number of Participants With Clinical Remission at Week 8 (As Per US Definition) (Week 8); Maintenance Study: Number of Participants With Clinical Remission at Week 44 (As Per Global Definition) (Week 44); Maintenance Study: Number of Participants With Clinical Remission at Week 44 (as Per US Definition) (Week 44)
D: Percentage of Participants In Remission at Week 52 (Week 52)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Study of Effectiveness of Mental Health Interventions Among Torture Survivors on the Thailand-Burma Border
Brief Summary: The aim of the study is to determine the effectiveness of a transdiagnostic psychotherapy intervention - namely, Common Elements Treatment Approach (CETA) - in reducing the severity of mental health symptoms experienced by torture and violence survivors displaced from Burma into Thailand. Specifically, the intervention seeks to measure reductions (if any) in symptoms of depression and trauma.


Options:
A: Change in level of aggressive behaviour in children: Child Behavior Checklist (CBCL) 11/2-5 and 6-18, parent-report, sub-scale "Aggressive behaviour" (with 19 items (CBCL ½ - 5) and 18 items (CBCL 6-18), continuous sub-scale score (pre: Jan/Feb 2021; post: approx. 4 months after pre assessment (May/June 2021); follow-up: approx. 10 -12 months after pre-assessment (Dec 2021 - Feb 2022)); Change in prevalence of Externalising Disorders in Children (MINI-KID), binary total score (pre: Jan/Feb 2021; post: approx. 4 months after pre assessment (May/June 2021); follow-up: approx. 10 -12 months after pre-assessment (Dec 2021 - Feb 2022)); Change in Parent Daily Ratings (PDR): oppositional and aggressive sub scale (12 items), continuous sub-scale score (PLH group: after the first, third and fifth session. lecture: after the lecture, 2 and 4 weeks later)
B: Depression (10-16 weeks); Posttraumatic Stress Symptoms (10-16 weeks)
C: Change in Alcohol Use Disorders Identification Test (AUDIT) Scale Score From Baseline to 6-month Post-baseline. (Baseline and 6 months post-baseline)
D: Implementation - Reach (From baseline to 6 months); Clinical Effectiveness - AUDIT (From baseline to 6 months)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Study of Effectiveness of Mental Health Interventions Among Torture Survivors on the Thailand-Burma Border
Brief Summary: The aim of the study is to determine the effectiveness of a transdiagnostic psychotherapy intervention - namely, Common Elements Treatment Approach (CETA) - in reducing the severity of mental health symptoms experienced by torture and violence survivors displaced from Burma into Thailand. Specifically, the intervention seeks to measure reductions (if any) in symptoms of depression and trauma.


Options:
A: Depression (10-16 weeks); Posttraumatic Stress Symptoms (10-16 weeks)
B: Change of depression symptom from baseline at 3 and 6 months (0-3-6 months); Change of anxiety symptom from baseline at 3 and 6 months (0-3-6 months); Change of chronic pain symptom from baseline at 3 and 6 months (0-3-6 months); Change of anger from baseline at 3 and 6 months (0-3-6 months); Change of PTSD symptom from baseline at 3 and 6 months (0-3-6 months)
C: depression (On completion of intervention and six months post-intervention)
D: Clinician-Administered PTSD Scale (CAPS) (After 14 weeks of treatment)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Study of Effectiveness of Mental Health Interventions Among Torture Survivors on the Thailand-Burma Border
Brief Summary: The aim of the study is to determine the effectiveness of a transdiagnostic psychotherapy intervention - namely, Common Elements Treatment Approach (CETA) - in reducing the severity of mental health symptoms experienced by torture and violence survivors displaced from Burma into Thailand. Specifically, the intervention seeks to measure reductions (if any) in symptoms of depression and trauma.


Options:
A: PTSD diagnosis and severity score according to the Clinicians Administered PTSD Scale (CAPS) (4 & 9 months after completion of treatment)
B: depression symptom severity (3-6 months)
C: Severity of Trauma. This will be the difference in group mean score of severity of depression based on a sum of ratings of various standard depression symptoms from the Hopkins Symptom Checklist and locally defined symptoms. (After 12 counseling , 4-5 months)
D: Depression (10-16 weeks); Posttraumatic Stress Symptoms (10-16 weeks)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Study of Effectiveness of Mental Health Interventions Among Torture Survivors on the Thailand-Burma Border
Brief Summary: The aim of the study is to determine the effectiveness of a transdiagnostic psychotherapy intervention - namely, Common Elements Treatment Approach (CETA) - in reducing the severity of mental health symptoms experienced by torture and violence survivors displaced from Burma into Thailand. Specifically, the intervention seeks to measure reductions (if any) in symptoms of depression and trauma.


Options:
A: Percentage of Days Used Drugs or Alcohol (intake to delivery, an average of 21 weeks); Percentage of Days Used Drugs or Alcohol (delivery to 3 months post-delivery); Percentage of Days That Participants (Without a Baseline Diagnosis of Drug Abuse or Dependence) Used Drugs or Alcohol (intake to delivery, an average of 21 weeks); Percentage of Days That Participants (Without a Baseline Diagnosis of Drug Abuse or Dependence) Used Drugs or Alcohol (Delivery to 3 months post-delivery); Percentage of Days That Participants (With a Baseline Diagnosis of Drug Abuse or Dependence) Used Drugs or Alcohol (intake to delivery, an average of 21 weeks); Percentage of Days That Participants (With a Baseline Diagnosis of Drug Abuse or Dependence) Used Drugs or Alcohol (Delivery to 3 months post-delivery)
B: Increase in parental competence at nine intervals over 39 month study period (birth-3 year postpartum)
C: Depression (10-16 weeks); Posttraumatic Stress Symptoms (10-16 weeks)
D: Evaluation of smoking cessation verified by expired air carbon monoxide (12 weeks after baseline)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Study of Effectiveness of Mental Health Interventions Among Torture Survivors on the Thailand-Burma Border
Brief Summary: The aim of the study is to determine the effectiveness of a transdiagnostic psychotherapy intervention - namely, Common Elements Treatment Approach (CETA) - in reducing the severity of mental health symptoms experienced by torture and violence survivors displaced from Burma into Thailand. Specifically, the intervention seeks to measure reductions (if any) in symptoms of depression and trauma.


Options:
A: Depression (10-16 weeks); Posttraumatic Stress Symptoms (10-16 weeks)
B: Alcohol use (12 months); HIV viral load (12 months)
C: Alcohol: change in mean number of heavy drinking days in last month of study period compared with baseline (6 months); TB: successful treatment vs. non-successful treatment as defined by the WHO (6 months)
D: Post-intervention ASSIST screening score. (3 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Study of Effectiveness of Mental Health Interventions Among Torture Survivors on the Thailand-Burma Border
Brief Summary: The aim of the study is to determine the effectiveness of a transdiagnostic psychotherapy intervention - namely, Common Elements Treatment Approach (CETA) - in reducing the severity of mental health symptoms experienced by torture and violence survivors displaced from Burma into Thailand. Specifically, the intervention seeks to measure reductions (if any) in symptoms of depression and trauma.


Options:
A: Change in post-traumatic stress symptoms measured by UCLA-PTSD-RI (Post-intervention and 3 month)
B: Change on Beck Depression Inventory-II (Screening; baseline, 6-8 weeks after baseline and 4 months after baseline)
C: Percentage of Combined Improvement of Depressive Symptoms and CVD Risk Factors (24-months post-intervention)
D: Depression (10-16 weeks); Posttraumatic Stress Symptoms (10-16 weeks)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Family Planning-based Partner Abuse Intervention to Reduce Unintended Pregnancy
Brief Summary: This is a community-based participatory study to test a brief intervention to reduce risk for intimate partner violence (IPV) and associated unintended pregnancy among young, medically underserved women attending family planning (FP) clinics. Women ages 16-29 years utilizing FP clinics report higher rates of IPV compared to their same-age peers, experiences associated with unintended pregnancy. A critical mechanism connecting IPV with poor reproductive health is abusive partners' control of women's reproduction through condom refusal, pressuring women to get pregnant, and birth control sabotage, a phenomenon described as reproductive coercion. In the investigative team's pilot intervention study 53% of young women using FP clinics reported ever experiencing IPV, and 25% reported reproductive coercion, the combination of which was strongly associated with unintended pregnancy. The proposed reproductive coercion/partner violence intervention was developed collaboratively by community-based practitioners, advocates, and researchers, with significant input from FP clients. Designed to be implemented within routine FP care, maximizing feasibility and sustainability of this program, the intervention provides 1) client education and assessment regarding IPV and reproductive coercion; 2) discussion of harm reduction behaviors to reduce risk for unintended pregnancy and IPV victimization, and 3) supported referrals to IPV victim services. This is a full-scale RCT to assess the effects of this innovative program on IPV, reproductive coercion and unintended pregnancy, major health threats for medically underserved women. Evaluation of this intervention will involve random assignment of 25 FP clinics (unit of randomization) in Western PA to either intervention or control (i.e., standard-of-care) conditions. Female FP clients ages 16-29 (N=3600) will be assessed at baseline, 12-20 weeks (FU1), and 12 months (FU2) to assess intervention effects on knowledge and behaviors related to IPV, reproductive coercion and related harm reduction, as well as unintended pregnancy. Data will be collected via audio computer-assisted self-interview in English or Spanish. Chart extraction will track clinic utilization, pregnancy testing, and diagnosed pregnancies. Regression models appropriate for longitudinal data from cluster-randomized trials will be used to estimate intervention effects.


Options:
A: Reduction of risk behaviors:; Active smoking; Environmental Tobacco Smoke Exposure; Depression; Intimate Partner Violence
B: CAPS for PTSD symptoms and ASI for substance use (pre, mid treatment, post, 3-month follow-up, 6-month follow-up)
C: Change in partner violence victimization (summary score) (baseline to 12 months); Change in reproductive coercion (summary score) (baseline to12 months)
D: Self-efficacy (Change from Baseline in Self efficacy at 6 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Family Planning-based Partner Abuse Intervention to Reduce Unintended Pregnancy
Brief Summary: This is a community-based participatory study to test a brief intervention to reduce risk for intimate partner violence (IPV) and associated unintended pregnancy among young, medically underserved women attending family planning (FP) clinics. Women ages 16-29 years utilizing FP clinics report higher rates of IPV compared to their same-age peers, experiences associated with unintended pregnancy. A critical mechanism connecting IPV with poor reproductive health is abusive partners' control of women's reproduction through condom refusal, pressuring women to get pregnant, and birth control sabotage, a phenomenon described as reproductive coercion. In the investigative team's pilot intervention study 53% of young women using FP clinics reported ever experiencing IPV, and 25% reported reproductive coercion, the combination of which was strongly associated with unintended pregnancy. The proposed reproductive coercion/partner violence intervention was developed collaboratively by community-based practitioners, advocates, and researchers, with significant input from FP clients. Designed to be implemented within routine FP care, maximizing feasibility and sustainability of this program, the intervention provides 1) client education and assessment regarding IPV and reproductive coercion; 2) discussion of harm reduction behaviors to reduce risk for unintended pregnancy and IPV victimization, and 3) supported referrals to IPV victim services. This is a full-scale RCT to assess the effects of this innovative program on IPV, reproductive coercion and unintended pregnancy, major health threats for medically underserved women. Evaluation of this intervention will involve random assignment of 25 FP clinics (unit of randomization) in Western PA to either intervention or control (i.e., standard-of-care) conditions. Female FP clients ages 16-29 (N=3600) will be assessed at baseline, 12-20 weeks (FU1), and 12 months (FU2) to assess intervention effects on knowledge and behaviors related to IPV, reproductive coercion and related harm reduction, as well as unintended pregnancy. Data will be collected via audio computer-assisted self-interview in English or Spanish. Chart extraction will track clinic utilization, pregnancy testing, and diagnosed pregnancies. Regression models appropriate for longitudinal data from cluster-randomized trials will be used to estimate intervention effects.


Options:
A: Change from baseline in WHO Quality of Life-BREF at 6, 12, 18, and 24 months (Baseline, 3-, 6-,12-, 18-, and 24-month postpartum)
B: Discussion of family psychosocial problem; Referral of family psychosocial problem; Contacting community resources
C: Change in partner violence victimization (summary score) (baseline to 12 months); Change in reproductive coercion (summary score) (baseline to12 months)
D: Change in Intimate Partner Violence Victimization from Baseline (12 months)

Answer: C